EP0563239A4 - Zerstümmeltes interleukin-1-rezeptor-gen zur behandlung von arthritis. - Google Patents

Zerstümmeltes interleukin-1-rezeptor-gen zur behandlung von arthritis.

Info

Publication number
EP0563239A4
EP0563239A4 EP19920902630 EP92902630A EP0563239A4 EP 0563239 A4 EP0563239 A4 EP 0563239A4 EP 19920902630 EP19920902630 EP 19920902630 EP 92902630 A EP92902630 A EP 92902630A EP 0563239 A4 EP0563239 A4 EP 0563239A4
Authority
EP
European Patent Office
Prior art keywords
arthritis
treatment
receptor gene
truncated interleukin
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19920902630
Other languages
English (en)
French (fr)
Other versions
EP0563239A1 (de
Inventor
Joseph C Glorioso
Christopher H Evans
Paul D Robbins
Geethani Bandara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of EP0563239A1 publication Critical patent/EP0563239A1/de
Publication of EP0563239A4 publication Critical patent/EP0563239A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP19920902630 1990-12-20 1991-12-09 Zerstümmeltes interleukin-1-rezeptor-gen zur behandlung von arthritis. Withdrawn EP0563239A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63098190A 1990-12-20 1990-12-20
US630981 1990-12-20
PCT/US1991/009231 WO1992011359A1 (en) 1990-12-20 1991-12-09 A truncated interleukin-1 receptor gene for the treatment of arthritis

Publications (2)

Publication Number Publication Date
EP0563239A1 EP0563239A1 (de) 1993-10-06
EP0563239A4 true EP0563239A4 (de) 1994-10-12

Family

ID=24529337

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19920902630 Withdrawn EP0563239A4 (de) 1990-12-20 1991-12-09 Zerstümmeltes interleukin-1-rezeptor-gen zur behandlung von arthritis.

Country Status (4)

Country Link
EP (1) EP0563239A4 (de)
JP (1) JPH06504440A (de)
CA (1) CA2098848A1 (de)
WO (1) WO1992011359A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159464A (en) * 1990-12-20 2000-12-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Viral vectors to inhibit leukocyte infiltration or cartilage degradation of joints
US6228356B1 (en) 1990-12-20 2001-05-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Viral vectors to inhibit leukocyte infiltration or cartilage degradation of joints
US6156304A (en) * 1990-12-20 2000-12-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for studying and treating a connective tissue of a mammalian host
US5858355A (en) * 1990-12-20 1999-01-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education IRAP gene as treatment for arthritis
US6413511B1 (en) * 1990-12-20 2002-07-02 University Of Pittsburgh Of The Commonwealth System Of Higher Education Cartilage alterations by administering to joints chondrocytes comprising a heterologous polynucleotide
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
AU684050B2 (en) * 1992-07-13 1997-12-04 Baylor College Of Medicine Targeting somatic gene therapy to joints
JPH08511507A (ja) * 1993-03-08 1996-12-03 ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 哺乳動物宿主の結合組織を処置するための遺伝子導入
US5645829A (en) * 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
WO1995003834A1 (en) * 1993-07-28 1995-02-09 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services PRE-BINDING OF RETROVIRAL VECTOR PARTICLES WITH COMPLEMENT COMPONENTS TO ENABLE THE PERFORMANCE OF HUMAN GENE THERAPY $i(IN VIVO)
AU1513495A (en) * 1993-12-14 1995-07-03 University Of Pittsburgh Systemic gene treatment of connective tissue diseases
JPH083058A (ja) * 1994-06-17 1996-01-09 Hoechst Japan Ltd 新規な骨代謝疾患治療剤
CA2198462A1 (en) * 1994-08-26 1996-03-07 Hans-Harald Sedlacek Genetic therapy of diseases caused by the immune system, said therapy using a cell-specific active substance regulated by the cell cycle
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
WO1999011292A2 (en) * 1997-09-02 1999-03-11 Chiron Corporation Compositions and methods for treating arthritis utilizing gene therapy
ES2312344T3 (es) 1999-05-28 2009-03-01 Targeted Genetics Corporation Metodos y composiciones para disminuir el nivel de factor de necrosis tumoral (tnf) en trastornos asociados con tnf.
EP1939300A1 (de) 1999-05-28 2008-07-02 Targeted Genetics Corporation Verfahren und Zusammensetzung zur Senkung des Spiegels des Tumornekrosefaktors (TNF) bei TNF-assoziierten Leiden
WO2001013960A1 (en) * 1999-08-20 2001-03-01 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods for in vivo gene delivery to sites of cartilage damage
WO2002083080A2 (en) * 2001-04-17 2002-10-24 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
HUE040595T2 (hu) 2004-04-02 2019-03-28 Swedish Orphan Biovitrum Ab Publ Eljárás IL-1ra aggregációjának csökkentésére

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0318296A2 (de) * 1987-11-25 1989-05-31 Immunex Corporation Interleukin 1-Rezeptoren
WO1989004838A1 (en) * 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0318296A2 (de) * 1987-11-25 1989-05-31 Immunex Corporation Interleukin 1-Rezeptoren
WO1989004838A1 (en) * 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
M. ROBERTSON: "Gene therapy. Desperate appliances.", NATURE, vol. 320, 20 March 1986 (1986-03-20), LONDON, GB, pages 213 - 214 *
M. TSUDA ET AL.: "Retrovirus-mediated gene transfer into mouse cerebellar primary culture and its application to the neural transplantation.", BRAIN RESEARCH BULLETIN, vol. 24, no. 6, 1990, pages 787 - 792 *
P. ROUX ET AL.: "A versatile and potentially general approach to the targeting of specific cell types by retroviruses: Application to the infection of human cells by means of major histocompatibility complex class I and class II antigens by mouse ecotropic murine leukemia virus-derived viruses.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 86, no. 23, December 1989 (1989-12-01), WASHINGTON, DC, USA, pages 9079 - 9083 *
See also references of WO9211359A1 *
T. FRIEDMANN: "Progress toward human gene therapy.", SCIENCE, vol. 244, no. 4910, 16 June 1989 (1989-06-16), WASHINGTON, DC, USA, pages 1275 - 1281 *

Also Published As

Publication number Publication date
EP0563239A1 (de) 1993-10-06
WO1992011359A1 (en) 1992-07-09
CA2098848A1 (en) 1992-06-21
JPH06504440A (ja) 1994-05-26

Similar Documents

Publication Publication Date Title
EP0563239A4 (de) Zerstümmeltes interleukin-1-rezeptor-gen zur behandlung von arthritis.
EP0670716A4 (de) Geschmacksmaskierte pharmazeutische substanzen.
EP0598573A3 (en) Bone plate.
EP0569214A3 (de) Brutschrank mit Rüttler.
GR3025363T3 (en) Medicaments.
IL97339A0 (en) Collosion a voidance system
EP0583712A3 (de) Verfahren zur Herstellung von Bisphenolen.
SG49571A1 (en) Polymer cracking
EP0647707A3 (de) Thermokammer.
EP0602846A3 (en) Jogger/aerator.
GB2176996B (en) Adjustable support mechanism for a keyboard or the like
DE3874176D1 (en) Quaternaeres ammoniumsalz und elektrophotographischer toner.
ZA928302B (en) Device for ring section furnace.
DE58904130D1 (en) Elektrophotographischer toner.
PH31213A (en) Drug for neuroprotection.
EP0602178A4 (en) T cell receptor-based therapy for rheumatoid arthritis.
ZA931481B (en) Implants.
EP0586848A3 (de) Implantat.
GB2222416B (en) Processes using disilane
DE58903960D1 (en) Elektrophotographische toner.
EP0573920A3 (de) Verfahren zur Herstellung von Tetrachlorethylen.
ZA929873B (en) Process for the manufacture of 2-alkoxymethylacrolein.
EP0359142A3 (en) Case for calendar sheets or the like
ZA939626B (en) Pharmaceutical compounds.
GB9211151D0 (en) Medicine feeder

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930715

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19940824

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

RBV Designated contracting states (corrected)

Designated state(s): CH DE ES FR GB IT LI NL SE

17Q First examination report despatched

Effective date: 19980623

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

18D Application deemed to be withdrawn

Effective date: 20010911